JP2012525829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525829A5 JP2012525829A5 JP2012509035A JP2012509035A JP2012525829A5 JP 2012525829 A5 JP2012525829 A5 JP 2012525829A5 JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012525829 A5 JP2012525829 A5 JP 2012525829A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- isolated antibody
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17586009P | 2009-05-06 | 2009-05-06 | |
| US61/175,860 | 2009-05-06 | ||
| PCT/EP2010/056129 WO2010136311A2 (en) | 2009-05-06 | 2010-05-05 | Compositions and methods for antibodies targeting complement protein c3b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525829A JP2012525829A (ja) | 2012-10-25 |
| JP2012525829A5 true JP2012525829A5 (https=) | 2013-06-20 |
Family
ID=43063291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012509035A Pending JP2012525829A (ja) | 2009-05-06 | 2010-05-05 | 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100291106A1 (https=) |
| EP (1) | EP2427491A2 (https=) |
| JP (1) | JP2012525829A (https=) |
| KR (1) | KR20120088551A (https=) |
| CN (1) | CN102459334A (https=) |
| AR (1) | AR076655A1 (https=) |
| AU (1) | AU2010252156A1 (https=) |
| CA (1) | CA2760757A1 (https=) |
| CL (1) | CL2011002756A1 (https=) |
| CO (1) | CO6440515A2 (https=) |
| EA (1) | EA201101593A1 (https=) |
| EC (1) | ECSP11011445A (https=) |
| IL (1) | IL216061A0 (https=) |
| MA (1) | MA33402B1 (https=) |
| MX (1) | MX2011011754A (https=) |
| PE (1) | PE20120899A1 (https=) |
| SG (1) | SG175432A1 (https=) |
| TN (1) | TN2011000528A1 (https=) |
| TW (1) | TW201043638A (https=) |
| UY (1) | UY32612A (https=) |
| WO (1) | WO2010136311A2 (https=) |
| ZA (1) | ZA201107551B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| US8940490B2 (en) * | 2010-11-29 | 2015-01-27 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| CA2869477C (en) * | 2012-04-03 | 2020-06-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor c3 antibodies and uses thereof |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| MX2015006738A (es) * | 2012-11-29 | 2015-08-05 | Bayer Healthcare Llc | Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos. |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| WO2015054298A1 (en) * | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
| AU2014370404A1 (en) | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| CN110724691A (zh) | 2014-02-27 | 2020-01-24 | 阿勒根公司 | 补体因子Bb抗体 |
| WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| JP7477457B2 (ja) * | 2018-04-03 | 2024-05-01 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｃ３結合薬及びその使用方法 |
| US12110321B2 (en) * | 2018-06-11 | 2024-10-08 | Aarhus Universitet | Single domain antibodies for complement regulation |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| CA3214281A1 (en) * | 2021-03-19 | 2022-09-22 | Elpis Biopharmaceuticals | Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| CR20240265A (es) | 2021-12-22 | 2024-10-16 | Boehringer Ingelheim Int | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| EP4590697A2 (en) * | 2022-09-20 | 2025-07-30 | Visterra, Inc. | Treatment of complement mediated diseases and disorders with c3b-antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JP4764590B2 (ja) * | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| US7838165B2 (en) * | 2004-07-02 | 2010-11-23 | Kabushiki Kaisha Toshiba | Carbon fiber synthesizing catalyst and method of making thereof |
| US20090004183A1 (en) * | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| MX2007006593A (es) * | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| CA2625681C (en) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| RU2473563C2 (ru) * | 2007-06-07 | 2013-01-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ |
| CL2008003241A1 (es) * | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
-
2010
- 2010-05-04 US US12/773,246 patent/US20100291106A1/en not_active Abandoned
- 2010-05-05 PE PE2011001908A patent/PE20120899A1/es not_active Application Discontinuation
- 2010-05-05 AU AU2010252156A patent/AU2010252156A1/en not_active Abandoned
- 2010-05-05 WO PCT/EP2010/056129 patent/WO2010136311A2/en not_active Ceased
- 2010-05-05 SG SG2011080330A patent/SG175432A1/en unknown
- 2010-05-05 KR KR1020117029046A patent/KR20120088551A/ko not_active Withdrawn
- 2010-05-05 CN CN201080026538XA patent/CN102459334A/zh active Pending
- 2010-05-05 MA MA34415A patent/MA33402B1/fr unknown
- 2010-05-05 EA EA201101593A patent/EA201101593A1/ru unknown
- 2010-05-05 JP JP2012509035A patent/JP2012525829A/ja active Pending
- 2010-05-05 EP EP10747599A patent/EP2427491A2/en not_active Withdrawn
- 2010-05-05 TW TW099114417A patent/TW201043638A/zh unknown
- 2010-05-05 AR ARP100101527A patent/AR076655A1/es not_active Application Discontinuation
- 2010-05-05 CA CA2760757A patent/CA2760757A1/en not_active Abandoned
- 2010-05-05 MX MX2011011754A patent/MX2011011754A/es not_active Application Discontinuation
- 2010-05-06 UY UY0001032612A patent/UY32612A/es not_active Application Discontinuation
-
2011
- 2011-10-14 ZA ZA2011/07551A patent/ZA201107551B/en unknown
- 2011-10-19 TN TNP2011000528A patent/TN2011000528A1/en unknown
- 2011-10-31 IL IL216061A patent/IL216061A0/en unknown
- 2011-11-04 CO CO11150255A patent/CO6440515A2/es not_active Application Discontinuation
- 2011-11-04 CL CL2011002756A patent/CL2011002756A1/es unknown
- 2011-11-08 EC EC2011011445A patent/ECSP11011445A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012525829A5 (https=) | ||
| KR102482710B1 (ko) | 항-pd-1 항체, 이의 생산 방법 및 사용 방법 | |
| JP2020508655A5 (https=) | ||
| RU2020120539A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2021508469A5 (https=) | ||
| JP2012500020A5 (https=) | ||
| JP2017052784A5 (https=) | ||
| JP2015504421A5 (https=) | ||
| JP2010538608A5 (https=) | ||
| JP2013545738A5 (https=) | ||
| JP2018510617A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2017523786A5 (https=) | ||
| JP2013527762A5 (https=) | ||
| JP2013523184A5 (https=) | ||
| JP2016507523A5 (https=) | ||
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| JP2010502183A5 (https=) | ||
| JP2012530496A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas |